A Phase 1 Trial of Single Agent Reolysin in Patients with Relapsed Multiple Myeloma

INTRODUCTION: Reolysin®, a proprietary isolate of reovirus Type 3 Dearing, enters and preferentially induces apoptosis of malignant cells. RAS pathway activation has been associated with more efficient reoviral infectivity and enhanced oncolysis. Reovirus is currently in advanced solid tumor phase 1...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Cancer Res
Autors principals: Sborov, Douglas W, Nuovo, Gerard J, Stiff, Andrew, Mace, Thomas, Lesinski, Gregory B., Benson, Don M., Efebera, Yvonne A, Rosko, Ashley E., Pichiorri, Flavia, Grever, Michael R., Hofmeister, Craig C
Format: Artigo
Idioma:Inglês
Publicat: 2014
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4253985/
https://ncbi.nlm.nih.gov/pubmed/25294913
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-1404
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars